Materials: pioneer isolation and subsequent RNAseq of astrocytic nuclei from fresh-frozen human brain samples of patients suffering from major depression (MDD).
Task/Hypothesis: changes in the molecular profile of astrocytes may underlie metabolic reprogramming.
Solution: bioinformatics analysis of nuclei RNAseq data using the Intelliseq RNA-seq workflow.
Result: The novel protocol allows the detection of transcriptomic changes masked in bulk tissue. Astrocytes are a promising target space for psychiatry. The study revealed novel potential targets in MDD therapy.
The research was conducted by:
BioMed X Institute, Heidelberg, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany; Laboratory of Pharmacogenomics, Department of Molecular Neuropharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland; Intelliseq, Kraków, Poland; McGill Group for Suicide Studies, Douglas Mental Health University Institute, Montreal, Quebec, Canada; Department of Functional Neuroanatomy, Heidelberg University, Heidelberg, Germany; Łukasiewicz Research Network – PORT Polish Institute for Technology Development, Wrocław, Poland
Read the full story here: